García SN

Language: Spanish
References: 34
Page: 132-137
PDF size: 109.64 Kb.

ABSTRACT

Leptin is a cytokine derived of the adipose tissue (95%), it binds to its receptor in the hypothalamus and inhibits the neuropeptid Y and stimulates the POMC (pro-opiomalanocortin), increasing the sympathic activity and energy balance, therefore it inhibits food ingestion and stimulates the release of energy, regulates the intracellular lipid homeostasis and favors fatty acid oxidation. In obesity, leptin levels are increased and their soluble receptors are diminished; the inability of signaling the leptin receptor produces an increase in fatty acid synthesis, hypertriglyceridemia, hepatic and muscular esteatosis, insulin resistance, failure of the beta cells and diabetes mellitus. These alterations are present in the metabolic syndrome, lipodystrophia, and leptin genetic mutations. The mutations in leptin gene cause hyperphagia, severe obesity and insulin resistance. The administration of recombinant leptin in genetic mutations and lipodystrophia reduces obesity and its metabolic effects; nevertheless, its application in obesity does not have significant effects.

REFERENCES

1. Paraccchini V, Pedotti P, Taioli E. Genetics of leptin and obesity: A Huge Review. Am J Epidemiol 2005; 162: 101-114.

2. Ceddia RB. Review. Direct metabolic regulation in skeletal muscle and fat tissue by leptin: implications for glucose and fatty acids homeostasis. Int J Obes 2005; 29: 1175-1183.

3. Meier U, Gressner AM. Endocrine regulation of energy metabolism: Review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin, and resistin. Clin Chem 2004; 50: 1511-1525.

4. Sabogal JC, Muñoz L. Leptin in obstetrics and gynecology: A Review. Ob Gyn Survey 2001; 56: 225-230.

5. Montague CT, Faroqi IS, Whitehead JP et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 1997; 387: 903-908.

6. Strobel A, Issad T, Camoin L et al. A leptin missense mutation associated with hypogandism and morbid obesity. Natural Genetic 1998; 18: 213-215.

7. Ozata M, Ozdemir IC, Licinio J. Human leptin deficiency caused by a missense mutation: multiple endocrine defects, decreased sympathetic tone, and immune system dysfunction indicate new targets for leptin action, greater central than peripheral resistance to the effects of leptin, and spontaneous correction of leptin-mediated defects. J Clin Endocrinol Metab1999; 84: 3686-3695.

8. Farooqi IS, Jebb SA, Langmack et al. Effects of recombinant leptin therapy in a child with congenital deficiency. N Engl J Med 1999; 341: 879-84.

9. Farooqi IS, Matarese G, Lord GM et alt. Beneficial effects of leptin on obesity, T cel hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest 2002; 110: 1093-1103.

10. Considine RV, Sinha MK, Heiman ML et al. Serum inmunoreactive-leptin concentrations in normal-wieght and obese humans. N Engl J Med 1996; 334: 292-295.

11. Clement K, Vaisse C, Lahlou N et al. A mutation in the humna leptin receptor gene causes obesity and pituitary dysfunction. Nature 1998; 392: 398-401.

12. Abhiram Sahu. Minireview: A hypothalamic role in energy balance with special emphasis on leptin. Endocrinology 2004; 145: 2613-2620.

13. Bouret SG, Simerly RB. Minireview: Leptin and development of hypothalamic feeding circuits. Endocrinology 2004; 145: 2621-2626.

14. Bagnasco M, Dube MG, Kalra PS et al. Evidence for the existence of distinct central appetite, energy expenditure, and ghrelin stimulation pathways as revelead by hypotalamic site-specific leptin gene therapy. Endocrinology 2002; 143: 4409-4421.

15. Hou L, Grill HJ, Bjorbek C. Divergent regulation of proopiomelanocortin neurons by leptin in the nucleus of the solitary tract and in the arcuate hypothalamic nucleus. Diabetes 2006; 55: 567-573.

16. Unger RH. Minireview: weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome. Endocrinology 2003; 144: 5169-5165.

17. Bastarrachea R, Fuenmayor R, Brajkovich I et al. Entendiendo las causas de la obesidad a través de la biología celular del adiposito. Revisión. Rev Ven Endocrinol Metab 2005; 3: 20-29.

18. Unger R, Zhou YT, Orci L. Regulation of fatty acid homeostasis in cells: Novel role of leptin. Proc Natl Acad Sci USA 1999; 96: 2327-2332.

19. Kakuma T, Wang ZW, Pan W et al. Role of leptin in peroxisome proliferator-actived receptor gamma coactivator-1 expression. Endocrinology 2000; 141: 4576-4582.

20. Hall JE, Hildebrant DA, Kuo J. Obesity hypertension: role of leptin and sympathtic nervous system. Am J Hypert 2001; 14: 103S-15S.

21. Hall JE, Crook ED, Jones DW et al. Mechanism of obesity-associated cardiovascular and renal disease. Am J Med Sci 2002; 324: 127-137.

22. Whipple T, Sharkey N, Demers L et al. Leptin and the skeleton. Clin Endocrinol 2002; 57; 701-711.

23. Hasink SG, Sheslow DV, de Lancey E et al. Serum leptin in children with obesity. Relationship to gender and development. Pediatrics 1996; 98: 201-203.

24. Parmert MR, Radovick S, Boepple PA. Leptin leves in children with central prococius puberty. J Clin Endocrinol Metab 1998; 83: 2260-2265.

25. Shalitin S, Phillip M. Role of obesity and leptin in the pubertal process and pubertal growth: a review. Int J Obes 2003; 27: 869-874.

26. Andreelli F, Hanaire-Bautrin H, Laville M et al. Normal reproductive function in leptin-deficient patients with lipoatropic diabetes. J Clin Endocrinol Metab 2000; 85: 715-719.

27. Kratzch J, Höckel M, Kiess W. Leptin and pregnancy outcome. Curr Opin Obstet Gynecol 2000; 12: 501-505.

28. Chapman I, Wittert GA, Norman RJ. Circulating leptin concentrations in polycystic ovary syndrome relation to anthropometric and metabolic parameters. Clin Endocrinol (Oxf) 1997; 46: 175-181.

29. Oral EA, Simha V, Ruiz E et al. Leptin-replacement therapy for lipodystrophy. N Engl J Med 2002; 346: 570-578.

30. Oral EA, Javor ED, Ding L et al. Leptin Replacement therapy modulates circulating lymphocyte subsets and cytokine responsiveness in severe lipodystrophy. J Clin Endocrinol Metab 2006; 91: 621-628.

31. Mantzoros CS, Flier JS. Leptin as a therapeutic agent-trial and tribulations (editorial) J Clin Endocrinol Metab 2000; 85: 4000-4002.

32. Heymisfield SB, Greenberg AS, Fujioka K et al. Recominant leptin for weight loss in obese and lean adults: a randomized, controlled, doses-escalation trial. JAMA 1999; 282: 1568-1575.

33. Hukshorn CJ, Saris WH, Westerterp-Pantenga W. Subcutaneous pegylated recombinant native human leptin (PEG-OB) administration in obese men. J Clin Endocrinol Metab 2000; 85: 4003-4009.

34. Hukshorn CJ, Van Dielen FM, Buurman WA et al The effect of pegylated recombinant human leptin (PEG_OB) on weight loss and inflammatory status in obeses subjects. Int J Obes Relat Metab Disord 2002; 26: 504-509.